{"id":"memantine-hydrochloride-tablets","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5%","effect":"Confusion"},{"rate":"5%","effect":"Constipation"},{"rate":"2-4%","effect":"Hypertension"},{"rate":"2-3%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1699","moleculeType":"Small molecule","molecularWeight":"215.77"},"_dailymed":{"setId":"802cbfd0-0dbe-638f-e053-2991aa0a6841","title":"GENERIC DRUG (MEMANTINE HYDROCHLORIDE TABLETS) TABLET [NINGBO SHOUZHENG MEDICINAL RESEARCH CO., LTD]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Memantine blocks the NMDA receptor ion channel in a use-dependent manner, allowing it to preferentially inhibit pathological overactivation of glutamate signaling while preserving normal synaptic transmission. This mechanism protects neurons from excitotoxic damage associated with neurodegenerative conditions. The drug is thought to restore the balance of neuronal activity disrupted in Alzheimer's disease and other cognitive disorders.","oneSentence":"Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that reduces excessive glutamate-mediated neuronal excitotoxicity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:00:18.155Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe Alzheimer's disease"},{"name":"Mild to moderate Alzheimer's disease (in combination with cholinesterase inhibitors)"}]},"trialDetails":[{"nctId":"NCT04302870","phase":"PHASE2, PHASE3","title":"Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2020-02-27","conditions":"Motor Neuron Disease, Amyotrophic Lateral Sclerosis","enrollment":1150},{"nctId":"NCT03553875","phase":"PHASE3","title":"Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2018-11-13","conditions":"Autism, Autism Spectrum Disorder, Nonverbal Learning Disability","enrollment":25},{"nctId":"NCT07417670","phase":"PHASE4","title":"Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease","status":"COMPLETED","sponsor":"Carnot Laboratories","startDate":"2024-10-04","conditions":"Alzheimer Disease","enrollment":105},{"nctId":"NCT05063851","phase":"PHASE2","title":"The Use of Memantine for Prevention of Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Virginia","startDate":"2021-10-11","conditions":"Alzheimer Disease","enrollment":32},{"nctId":"NCT05418049","phase":"PHASE2","title":"Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2022-09-08","conditions":"Fragile X Syndrome","enrollment":45},{"nctId":"NCT07251023","phase":"PHASE3","title":"Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia","status":"RECRUITING","sponsor":"Bigespas LTD","startDate":"2025-11-20","conditions":"Alzheimer Type Dementia","enrollment":450},{"nctId":"NCT06501638","phase":"PHASE2","title":"Efficacy and Safety of memanTine in the Treatment Of Frequently symPtomatic Atrial Premature Beats","status":"COMPLETED","sponsor":"Shanghai East Hospital","startDate":"2024-08-29","conditions":"Atrial Premature Beats, Contractions, or Systoles","enrollment":256},{"nctId":"NCT00262470","phase":"PHASE1, PHASE2","title":"Treatment of Orthostatic Intolerance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Satish R. Raj","startDate":"1997-04","conditions":"Tachycardia, Chronic Orthostatic Intolerance","enrollment":150},{"nctId":"NCT05564169","phase":"PHASE3","title":"Masitinib in Patients With Mild Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"AB Science","startDate":"2026-06","conditions":"Alzheimer Disease","enrollment":600},{"nctId":"NCT06041789","phase":"PHASE2","title":"Effect of Acetylcholinesterase Inhibitors on Bone Metabolism","status":"RECRUITING","sponsor":"Duke University","startDate":"2025-02-03","conditions":"Osteoporosis","enrollment":45},{"nctId":"NCT06275035","phase":"PHASE3","title":"Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI","status":"RECRUITING","sponsor":"Tata Memorial Centre","startDate":"2024-02-22","conditions":"Neurocognitive Dysfunction","enrollment":101},{"nctId":"NCT04789915","phase":"PHASE1","title":"Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis","status":"RECRUITING","sponsor":"Bjorn H. Ebdrup","startDate":"2021-05-26","conditions":"Psychosis, Negative Symptoms With Primary Psychotic Disorder","enrollment":46},{"nctId":"NCT06679387","phase":"PHASE2","title":"\"The Effect of Memantine on the Prevention and Amelioration of Paclitaxel-induced Toxicity in Breast Cancer Patients\"","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2024-10-30","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":80},{"nctId":"NCT06594172","phase":"PHASE2","title":"Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2024-09-10","conditions":"Radiation Disease, Cognitive Impairment, Drug Effect","enrollment":67},{"nctId":"NCT03670095","phase":"PHASE1","title":"Study in Healthy Subjects to Compare Two Tablet Formulations of Memantine (Ebixa®) in Fasted and Fed Conditions","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2018-08-28","conditions":"Healthy","enrollment":64},{"nctId":"NCT01872598","phase":"PHASE3","title":"Masitinib in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"AB Science","startDate":"2012-01","conditions":"Alzheimer Disease","enrollment":721},{"nctId":"NCT02580305","phase":"PHASE2","title":"SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study","status":"COMPLETED","sponsor":"Suven Life Sciences Limited","startDate":"2015-09","conditions":"Alzheimer's Disease","enrollment":564},{"nctId":"NCT05804279","phase":"PHASE1","title":"Pharmacokinetics of BPDO-1603 or BPDO-16031 and BPDO-16033 Administration in Healthy Adults","status":"COMPLETED","sponsor":"Hyundai Pharm","startDate":"2022-12-28","conditions":"Healthy","enrollment":24},{"nctId":"NCT02118727","phase":"PHASE2","title":"Therapy in Amyotrophic Lateral Sclerosis (TAME)","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-11-07","conditions":"Amyotrophic Lateral Sclerosis, Frontal Temporal Dementia","enrollment":89},{"nctId":"NCT05430867","phase":"PHASE4","title":"Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-07-01","conditions":"Treatment, Efficacy, Safety","enrollment":150},{"nctId":"NCT05015595","phase":"PHASE3","title":"Memantine for Refractory OCD Patients","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2021-09-01","conditions":"Obsessive-Compulsive Disorder","enrollment":20},{"nctId":"NCT03988803","phase":"PHASE1","title":"A Study in Healthy Men and Women to Test Which Effects Memantine and BI 425809 Have on Each Other","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-07-17","conditions":"Healthy","enrollment":16},{"nctId":"NCT04737967","phase":"PHASE2, PHASE3","title":"The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Mendel AI","startDate":"2021-02-15","conditions":"Oncology Pain, Chemotherapy-induced Peripheral Neuropathy","enrollment":60},{"nctId":"NCT03858270","phase":"PHASE3","title":"Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine","status":"UNKNOWN","sponsor":"Wayne State University","startDate":"2019-04-01","conditions":"Parkinson Disease","enrollment":50},{"nctId":"NCT04417543","phase":"PHASE1","title":"Effect of Memantine on Cognitive Impairment in Patients With Epilepsy","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-10-01","conditions":"Epilepsy","enrollment":100},{"nctId":"NCT01458470","phase":"PHASE2","title":"A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-09","conditions":"Huntington Disease","enrollment":19},{"nctId":"NCT03247218","phase":"PHASE2","title":"A Phase - IIa - IIb, Trial to Study the Safety, Tolerability and Efficacy of Memantine as a Long-term Treatment of SCD","status":"UNKNOWN","sponsor":"HaEmek Medical Center, Israel","startDate":"2018-02-02","conditions":"Sickle Cell Disease","enrollment":40},{"nctId":"NCT02553928","phase":"PHASE4","title":"Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-10","conditions":"Alzheimer Dementia (AD)","enrollment":62},{"nctId":"NCT03121820","phase":"PHASE1","title":"Fasting Bioequivalence Study of Memantinol 20 mg Tablets Versus Akatinol Memantine® 20 mg Tablets In Normal Healthy Subjects","status":"COMPLETED","sponsor":"Geropharm","startDate":"2016-10-11","conditions":"Bioequivalence, AUC, Cmax, Pharmacokinetics","enrollment":18},{"nctId":"NCT02079246","phase":"PHASE3","title":"Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2014-04-07","conditions":"Alzheimer's Disease","enrollment":1463},{"nctId":"NCT00586066","phase":"PHASE4","title":"Memantine and Cognitive Dysfunction in Bipolar Disorder","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2005-11","conditions":"Bipolar Disorder","enrollment":72},{"nctId":"NCT00294554","phase":"NA","title":"Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2006-04","conditions":"Parkinson's Disease, Cognitive Impairment, Dementia","enrollment":20},{"nctId":"NCT01054599","phase":"NA","title":"Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?","status":"COMPLETED","sponsor":"American Academy of Neurology","startDate":"2009-01","conditions":"Epilepsy","enrollment":29},{"nctId":"NCT03168997","phase":"PHASE4","title":"Memantine Treatment in Alzheimer's Disease Patients","status":"UNKNOWN","sponsor":"Wei Cuibai","startDate":"2017-07-15","conditions":"Alzheimer Disease","enrollment":222},{"nctId":"NCT01392287","phase":"PHASE1","title":"Treatment Resistant Geriatric Depression in Primary Care","status":"COMPLETED","sponsor":"Mclean Hospital","startDate":"2010-05","conditions":"Major Depressive Disorder","enrollment":12},{"nctId":"NCT00462228","phase":"PHASE4","title":"Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury","status":"TERMINATED","sponsor":"University of Missouri-Columbia","startDate":"2007-04","conditions":"Traumatic Brain Injury","enrollment":11},{"nctId":"NCT00638027","phase":"PHASE4","title":"Memantine for Spasticity in MS Patients","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2006-07","conditions":"Multiple Sclerosis","enrollment":21},{"nctId":"NCT02246075","phase":"PHASE2","title":"Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine","status":"WITHDRAWN","sponsor":"FORUM Pharmaceuticals Inc","startDate":"2015-07","conditions":"Alzheimer's Disease, Dementia, Cognition","enrollment":""},{"nctId":"NCT02570581","phase":"PHASE1","title":"MELA Study - Hedonic Study on the Taste of Drugs Crushed in Food: Observational Study Involving 16 Healthy Volunteers","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2014-06","conditions":"Healthy","enrollment":16},{"nctId":"NCT00630500","phase":"PHASE2","title":"Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)","status":"COMPLETED","sponsor":"Helse Stavanger HF","startDate":"2006-02","conditions":"Dementia Associated With Parkinson's Disease, Dementia With Lewy Bodies","enrollment":75},{"nctId":"NCT01052662","phase":"PHASE2, PHASE3","title":"Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2009-10","conditions":"Opioid Dependence","enrollment":87},{"nctId":"NCT01461174","phase":"PHASE1","title":"Effects of Donepezil and Memantine on Cognitive Functions After a Sleep Deprivation Challenge in Healthy Volunteers","status":"COMPLETED","sponsor":"Qualissima","startDate":"2011-11","conditions":"Healthy","enrollment":36},{"nctId":"NCT00411398","phase":"PHASE3","title":"A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"State University of New York - Upstate Medical University","startDate":"2006-12","conditions":"General Anxiety Disorder, Social Anxiety Disorder","enrollment":15},{"nctId":"NCT00933608","phase":"PHASE4","title":"Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2009-07","conditions":"Alzheimer's Disease","enrollment":17},{"nctId":"NCT00476008","phase":"PHASE4","title":"Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease","status":"COMPLETED","sponsor":"Florida Atlantic University","startDate":"2007-07","conditions":"Alzheimer's Disease","enrollment":60},{"nctId":"NCT00235716","phase":"PHASE3","title":"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2007-08","conditions":"Alzheimer's Disease","enrollment":613},{"nctId":"NCT01626391","phase":"PHASE2","title":"Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease","status":"TERMINATED","sponsor":"TauRx Therapeutics Ltd","startDate":"2012-09","conditions":"Alzheimer's Disease","enrollment":9},{"nctId":"NCT02136823","phase":"NA","title":"Impact of Persistent Conductances on Motor Unit Firing in SCI","status":"UNKNOWN","sponsor":"Shirley Ryan AbilityLab","startDate":"2009-06","conditions":"Chronic Spinal Cord Injury","enrollment":50},{"nctId":"NCT00857649","phase":"PHASE3","title":"Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2003-12","conditions":"Alzheimer's Disease","enrollment":369},{"nctId":"NCT01261741","phase":"PHASE2","title":"Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2010-11","conditions":"Memory Disorder, Retention Disorder, Cognitive, Subjective Cognitive Impairment","enrollment":299},{"nctId":"NCT00804271","phase":"PHASE3","title":"Memantine and Validation of a New Alzheimer's Disease Scale","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2008-12","conditions":"Alzheimer's Disease","enrollment":487},{"nctId":"NCT00862940","phase":"PHASE4","title":"A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2005-09","conditions":"Alzheimer's Disease","enrollment":277},{"nctId":"NCT00857233","phase":"PHASE3","title":"Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2004-06","conditions":"Alzheimer's Disease","enrollment":297},{"nctId":"NCT01653457","phase":"PHASE3","title":"Randomised Controlled Trial of Memantine in Fibromyalgia","status":"UNKNOWN","sponsor":"Aragon Institute of Health Sciences","startDate":"2012-09","conditions":"Fibromyalgia","enrollment":60},{"nctId":"NCT00586573","phase":"PHASE4","title":"Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2007-03","conditions":"ADHD","enrollment":34},{"nctId":"NCT00594737","phase":"PHASE3","title":"Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia","status":"COMPLETED","sponsor":"Tiffany Chow, MD","startDate":"2007-10","conditions":"Frontotemporal Dementia","enrollment":17},{"nctId":"NCT01108029","phase":"PHASE4","title":"Study of Memantine for Gait Disorders And Attention Deficit In Parkinson's Disease","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2009-10","conditions":"Parkinson's Disease, Gait Disorders, Neurologic","enrollment":28},{"nctId":"NCT00649220","phase":"PHASE4","title":"Memantine and Antipsychotics Use","status":"TERMINATED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2008-07","conditions":"Alzheimer's Disease","enrollment":19},{"nctId":"NCT01041313","phase":"PHASE4","title":"Memantine for Post-Operative Pain Control","status":"UNKNOWN","sponsor":"University of Washington","startDate":"2010-01","conditions":"Pain, Post-operative","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Memantine Hydrochloride Tablets","genericName":"Memantine Hydrochloride Tablets","companyName":"University of Virginia","companyId":"university-of-virginia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that reduces excessive glutamate-mediated neuronal excitotoxicity. Used for Moderate to severe Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}